Weight Loss Drugs Like Wegovy Could Have Linked Anesthesia Complications, European Medicines Agency To Investigate
Portfolio Pulse from Vandana Singh
The European Medicines Agency (EMA) is set to investigate potential complications linked to weight loss drugs such as Novo Nordisk's Wegovy and Ozempic, Eli Lilly's Mounjaro and Trulicity, and drugs made by AstraZeneca and Sanofi. The complications could lead to pneumonia during anesthesia. The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) will discuss this issue in its regular monthly meetings.
September 27, 2023 | 12:49 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AstraZeneca's weight loss drugs are under investigation by the EMA for potential complications during anesthesia.
The investigation by the EMA could potentially lead to regulatory actions that may impact the sales and reputation of AstraZeneca's weight loss drugs.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Eli Lilly's weight loss drugs Mounjaro and Trulicity are under investigation by the EMA for potential complications during anesthesia.
The investigation by the EMA could potentially lead to regulatory actions that may impact the sales and reputation of Eli Lilly's weight loss drugs.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Novo Nordisk's weight loss drugs Wegovy and Ozempic are under investigation by the EMA for potential complications during anesthesia.
The investigation by the EMA could potentially lead to regulatory actions that may impact the sales and reputation of Novo Nordisk's weight loss drugs.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Sanofi's weight loss drugs are under investigation by the EMA for potential complications during anesthesia.
The investigation by the EMA could potentially lead to regulatory actions that may impact the sales and reputation of Sanofi's weight loss drugs.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100